Clinical relevance of F-18 -FDG PET/CT in the follow-up of patients with operated medullary thyroid cancer. Is there any additional value of other radionuclide methods?
FDG PET/CT in medullary cancer
Objective: The aim is evaluation of 18F-FDG PET/CT in the detection of active disease in the patients with suspected recurrence of the medullary thyroid carcinoma (MTC).
Methods: 18F-FDG PET/CT investigation was performed in 67 patients. Additionally, 25 underwent 99mTc-DMSA scintigraphy, 11 underwent somatostatin receptor scintigraphy (SRS) with 99mTc- HYNIC TOC while 11 123I-MIBG scintigraphy.
Results: From 67 patients, 35 (52.2%) had true positive 18F-FDG PET/CT findings (TP). Average standardized uptake value (SUVmax) for all TP lesions was 5.01 + 3.6. In 25 (37.3%) patients findings were true negative (TN). Four (6%) patients had false positive (FP) findings while three (4.5%) were false negative (FN). Thus, sensitivity of the 18F-FDG PET/CT was 92.11%, specificity 86.21%, positive predictive value 89.74%, negative predictive value 89.29% and accuracy 89.55%. In 27 patients (40%) 18F-FDG PET/CT finding influenced further management of the patient.
Conclusion: 18F-FDG PET/CT has high accuracy in the detection of metastases/recurrences of MTC in patients after thyroidectomy as well as in evaluation and the appropriate choice of the therapy.
Copyright (c) 2021 Radiology and Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to email@example.com